Breaking News Instant updates and real-time market news.

INTC

Intel

$50.78

-0.15 (-0.29%)

, AMD

AMD

$28.73

-0.73 (-2.48%)

08:19
09/30/19
09/30
08:19
09/30/19
08:19

China macro improves as tech independence accelerates, says Susquehanna

Susquehanna analyst Christopher Rolland said his trip to Asia revealed an improving macro environment as china accelerates its plans for technological independence. The analyst noted CPU shortages at both Intel (INTC) and AMD (AMD) as well as expectations for an (AAPL) Apple iPhones sales peak expected in October.

INTC

Intel

$50.78

-0.15 (-0.29%)

AMD

AMD

$28.73

-0.73 (-2.48%)

AAPL

Apple

$218.91

-0.99 (-0.45%)

  • 24

    Oct

  • 07

    Nov

INTC Intel
$50.78

-0.15 (-0.29%)

09/19/19
SUSQ
09/19/19
NO CHANGE
Target $34
SUSQ
Neutral
AMD continues to take market share, says Susquehanna
Susquehanna analyst Christopher Rolland said AMD (AMD) continues to take market share at Intel's (INTC) expense. He sees potential upside due to new IP licensing agreements, increasing design wins in the data center, and share gains in GPU's. Rolland maintained his Neutral rating and $34 price target on AMD shares.
09/20/19
MZHO
09/20/19
NO CHANGE
MZHO
Mizuho checks indicate computer CPU and GPUs are trending better
Mizuho analyst Vijay Rakesh says his channel checks indicate computer CPU and GPUs are trending better in Q3 with new product launches, but also some pull-ins ahead of potential Q4 tariffs. The analyst believes Intel (INTC) is "opportunistically and aggressively" pricing its i3 processor, although he expects AMD (AMD) to pick up some share into year-end. In data center, Rakesh believes AMD's ramp could be slowed by price competition and testing. The analyst also remains positive on Western Digital (WDC) and Micron Technology (MU) into earnings, citing better pricing and PC trends. He maintains Buy ratings on Intel and Nvidia (NVDA, and a Neutral on rating AMD.
09/24/19
WEDB
09/24/19
NO CHANGE
Target $245
WEDB
Outperform
Apple makes 'smart poker move' with Austin shift, says Wedbush
Wedbush analyst Daniel Ives notes that Apple (AAPL) announced that it will commit to building its redesigned Mac Pro in Austin, Texas after securing tariff exemption on a majority of its requests, including partially assembled main circuit boards and graphics cards which contain chips from Intel (INTC), Nvidia (NVDA), and AMD (AMD). The analyst believes "this is an example of smart and strategic balanced production" from Apple and should be viewed as a move in good faith heading into the December 15th possibility of the additional 10% tariff on the $300B of Chinese goods. On the supply chain, Ives thinks Apple is aggressively looking at alternative options within the supply chain around moving 5%-7% of iPhone production to India and/or Vietnam, away from China, which would in a best case scenario be ready to roll 18 months from now. The analyst believes the China overhang has resulted in a $20-$25 hit to Apple's stock, and would be a buyer of Apple stock. Ives reiterates an Outperform rating and $245 price target on the shares.
09/30/19
NOMU
09/30/19
NO CHANGE
NOMU
Nomura Instinet still cautious on semiconductors after Micron report
Micron Technology (MU) last week provided November quarter guidance for a 37% year-over-year decline in sales and a further drop in gross margin, to 25.5%, Nomura Instinet analyst David Wong tells investors in a research note titled "Little Evidence of Recovery Yet." Further, August global chip shipment data showed a continuing year-over-year decline in the mid- to high-teens range, adds the analyst. Wong remains cautious on the semiconductor and semiconductor equipment industry overall.
AMD AMD
$28.73

-0.73 (-2.48%)

AAPL Apple
$218.91

-0.99 (-0.45%)

09/26/19
KEYB
09/26/19
NO CHANGE
KEYB
Sector Weight
Apple Services narrative largely priced in, says KeyBanc
KeyBanc analyst Andy Hargreaves believes Apple's Services narrative is largely priced in, as the stock's valuation no longer appears attractive relative to other large services businesses. This suggests profit growth will be needed to drive stock appreciation going forward, which will require a trend reversal in either user growth or gross profit per user, both of which appear difficult. He reiterates a Sector Weight rating on the shares.
09/26/19
UBSW
09/26/19
NO CHANGE
Target $235
UBSW
Buy
Apple iPhone launch 'appears strong' in U.S., says UBS
UBS analyst Timothy Arcuri said his spot checks and data from the firm's Evidence Lab do not suggest the type of short-falls in iPhone sales that were seen last year and that the launch "appears strong at least in the US." Five days after the launch, Evidence Lab availability data suggests longer wait times for iPhone 11/Pro relative to last year's iPhone XR/Xs, noted Arcuri, who is still modeling second half iPhone shipments to be down 5.3%, which he noted is slightly worse than the consensus projection for a 4.4% decline. Arcuri maintains a Buy rating and $235 price target on Apple shares.
09/27/19
JPMS
09/27/19
NO CHANGE
Target $425
JPMS
Overweight
JPMorgan reiterates Overweight on Netflix with stock down 12% in seven days
Netflix (NFLX) shares are down 27% since the Q2 earnings report, including down 12% over the past seven trading days, due to increased concern around Q3 net additions, especially in international markets, and heightened competition heading toward year-end and into 2020 from Disney+ (DIS), Apple TV+ (AAPL), and HBO Max (T), JPMorgan analyst Doug Anmuth tells investors in a research note. While the operating environment is changing, global disruption of linear TV is a "strong secular trend" that remains early stage in many international markets, and Netflix will remain a key beneficiary as more people cut the cord, says Anmuth. Further, the analyst believes Netflix has "significant advantages" around data and also its breadth and depth of content. In addition, the bar for Q3 has come down, says Anmuth, who keeps an Overweight rating on Netflix with a $425 price target.
09/30/19
JPMS
09/30/19
NO CHANGE
Target $265
JPMS
Overweight
Apple price target raised to $265 from $243 at JPMorgan
JPMorgan analyst Samik Chatterjee established a December 2020 price target for Apple shares of $265, up from his from his December 2019 target to $243. The stock closed Friday down $1.07 to $218.82. The analyst keeps an Overweight rating on Apple. Chatterjee "modestly" raised his iPhone volume forecasts and expects investor sentiment on Apple shares to "improve materially" given the company's ability to drive upward revisions to volume expectations. The 2019 product cycle is largely considered to be a "muted one" due to limited hardware enhancements and replacement cycle risks amid expectations for a 5G phone next year, Chatterjee tells investors in a research note. The analyst, however, raised his iPhone volume forecasts for Apple's September quarter by 1M and for its December quarter by 3M units to account for stronger trends, particularly led by the iPhone 11 model amongst the new iPhones. He believes volume upside in 2019 will have significance in demonstrating that Apple can deliver balance of volume and profitability "even in a tough backdrop."

TODAY'S FREE FLY STORIES

HPQ

HP Inc.

$20.17

0.05 (0.25%)

, XRX

Xerox

$38.95

0.295 (0.76%)

20:56
11/17/19
11/17
20:56
11/17/19
20:56
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

HPQ

HP Inc.

$20.17

0.05 (0.25%)

XRX

Xerox

$38.95

0.295 (0.76%)

GOLD

Barrick Gold

$16.57

-0.095 (-0.57%)

PCG

PG&E

$7.41

0.71 (10.60%)

FOX

Fox Corp.

$33.60

0.14 (0.42%)

FOXA

Fox Corp.

$34.26

0.04 (0.12%)

SNE

Sony

$62.03

0.23 (0.37%)

BR

Broadridge

$119.80

0.485 (0.41%)

MDT

Medtronic

$112.11

2.9 (2.66%)

DIS

Disney

$144.63

-2.56 (-1.74%)

BRK.A

Berkshire Hathaway

$329,361.11

266.11 (0.08%)

BRK.B

Berkshire Hathaway

$219.74

0.38 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 26

    Nov

  • 09

    Dec

  • 07

    Jan

RCEL

Avita Medical

$8.13

-0.06 (-0.73%)

20:39
11/17/19
11/17
20:39
11/17/19
20:39
Hot Stocks
Avita Medical appoints David McIntyre CFO »

AVITA Medical announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EIDX

Eidos Therapeutics

$46.58

1.33 (2.94%)

20:37
11/17/19
11/17
20:37
11/17/19
20:37
Recommendations
Eidos Therapeutics analyst commentary  »

Piper Jaffray sees Eidos…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 21

    Nov

COO

Cooper Companies

$301.97

2.64 (0.88%)

20:30
11/17/19
11/17
20:30
11/17/19
20:30
Recommendations
Cooper Companies analyst commentary  »

Piper Jaffray reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CRM

Salesforce

$163.20

0.18 (0.11%)

20:21
11/17/19
11/17
20:21
11/17/19
20:21
Recommendations
Salesforce analyst commentary at Jefferies »

Salesforce price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

  • 16

    Dec

CCMP

Cabot Microelectronics

$155.89

2.68 (1.75%)

20:15
11/17/19
11/17
20:15
11/17/19
20:15
Earnings
Breaking Earnings news story on Cabot Microelectronics »

Cabot Microelectronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

CCMP

Cabot Microelectronics

$155.89

2.68 (1.75%)

20:15
11/17/19
11/17
20:15
11/17/19
20:15
Earnings
Cabot Microelectronics sees Q1 total revenue approximately flat »

For Q1, the company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

CCMP

Cabot Microelectronics

$155.89

2.68 (1.75%)

20:14
11/17/19
11/17
20:14
11/17/19
20:14
Earnings
Cabot Microelectronics reports Q4 EPS $1.68, consensus $1.63 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

JEF

Jefferies Financial Group

$19.08

0.16 (0.85%)

20:13
11/17/19
11/17
20:13
11/17/19
20:13
Hot Stocks
Jefferies Financial Group to sell 31% interest in National Beef to Marfrig »

Jefferies Financial Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NIO

NIO Inc.

$1.82

0.07 (4.01%)

20:11
11/17/19
11/17
20:11
11/17/19
20:11
Hot Stocks
NIO Inc. appoints Wei Feng CFO »

NIO Inc. announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOLD

Barrick Gold

$16.57

-0.095 (-0.57%)

20:09
11/17/19
11/17
20:09
11/17/19
20:09
Hot Stocks
Barrick Gold to sell 50% stake in Australian mine for $750M in cash »

Barrick Gold Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOLD

Barrick Gold

$16.57

-0.095 (-0.57%)

15:40
11/17/19
11/17
15:40
11/17/19
15:40
Periodicals
Saracen close to buying Barrick Gold mine stake for $750M, Bloomberg says »

Saracen Mineral Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESPR

Esperion

$40.51

0.67 (1.68%)

15:11
11/17/19
11/17
15:11
11/17/19
15:11
Hot Stocks
Esperion presents pooled analyses from four Phase 3 bempedoic acid studies »

Esperion announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Feb

PCG

PG&E

$7.41

0.71 (10.60%)

15:06
11/17/19
11/17
15:06
11/17/19
15:06
Hot Stocks
PG&E monitoring potential weather event that could lead to power shutoffs »

Pacific Gas and Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

XRX

Xerox

$38.95

0.295 (0.76%)

, HPQ

HP Inc.

$20.17

0.05 (0.25%)

15:04
11/17/19
11/17
15:04
11/17/19
15:04
Hot Stocks
HP unanimously rejects unsolicited Xerox proposal »

HP Inc. (HPQ) announced…

XRX

Xerox

$38.95

0.295 (0.76%)

HPQ

HP Inc.

$20.17

0.05 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 09

    Dec

FOX

Fox Corp.

$33.60

0.14 (0.42%)

, FOXA

Fox Corp.

$34.26

0.04 (0.12%)

14:49
11/17/19
11/17
14:49
11/17/19
14:49
On The Fly
Box Office Battle: 'Ford v Ferrari' races to top, 'Charlie's Angels' disappoints »

"Box Office Battle" is…

FOX

Fox Corp.

$33.60

0.14 (0.42%)

FOXA

Fox Corp.

$34.26

0.04 (0.12%)

LGF.A

Lionsgate

$9.67

0.315 (3.37%)

LGF.B

Lionsgate

$9.07

0.345 (3.96%)

SNE

Sony

$62.03

0.23 (0.37%)

VIA

Viacom

$26.59

1.28 (5.06%)

VIAB

Viacom

$23.07

0.59 (2.62%)

T.CA

TELUS Corp. (Toronto)

$0.00

(0.00%)

CMCSA

Comcast

$44.54

-0.93 (-2.05%)

CMCSK

Comcast

$0.00

(0.00%)

DIS

Disney

$144.63

-2.56 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

13:36
11/17/19
11/17
13:36
11/17/19
13:36
Periodicals
J&J rushed to test baby powder and got complicated results, WSJ says »

In October, Johnson &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 07

    Dec

  • 21

    Jan

BA

Boeing

$371.55

4.25 (1.16%)

13:24
11/17/19
11/17
13:24
11/17/19
13:24
Periodicals
Boeing 737 makes emergency landing after engine malfunction, NY Post says »

A Canada-bound flight…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$47.46

0.09 (0.19%)

13:17
11/17/19
11/17
13:17
11/17/19
13:17
Hot Stocks
Data shows AstraZeneca's Brilinta reduces risks of clinically relevant bleeding »

New results from a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 07

    Dec

LLY

Eli Lilly

$113.18

1.8 (1.62%)

13:11
11/17/19
11/17
13:11
11/17/19
13:11
Hot Stocks
Analysis shows Jardiance decreased risk of hospitalization for heart failure »

A new interim analysis of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

AZN

AstraZeneca

$47.46

0.09 (0.19%)

13:09
11/17/19
11/17
13:09
11/17/19
13:09
Hot Stocks
AstraZeneca says data shows Farxiga reduces risks in heart failure patients »

AstraZeneca announced new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 07

    Dec

BA

Boeing

$371.55

4.25 (1.16%)

13:05
11/17/19
11/17
13:05
11/17/19
13:05
Hot Stocks
Boeing, Biman announce order for two 787-9 Dreamliner jets »

Boeing and Biman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBIO

BridgeBio

$28.26

0.55 (1.98%)

, EIDX

Eidos Therapeutics

$46.58

1.33 (2.94%)

13:03
11/17/19
11/17
13:03
11/17/19
13:03
Hot Stocks
BridgeBio, Eidos present 'positive' data from Phase 2 clinical trial of AG10 »

BridgeBio Pharma (BBIO)…

BBIO

BridgeBio

$28.26

0.55 (1.98%)

EIDX

Eidos Therapeutics

$46.58

1.33 (2.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 21

    Nov

CLBS

Caladrius

$2.64

-0.06 (-2.22%)

13:01
11/17/19
11/17
13:01
11/17/19
13:01
Hot Stocks
Caladrius reports 'positive' results for CLBS16 from ESCaPE-CMD trial »

Caladrius Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KNSA

Kiniksa

$6.52

0.1 (1.56%)

12:59
11/17/19
11/17
12:59
11/17/19
12:59
Hot Stocks
Kiniksa presents Rilonacept final Phase 2 clinical data »

Kiniksa Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 21

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.